The part that got me the bottom paragraph.
Imugene has two HER2 B-cell vaccines in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both vaccines showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell vaccine technology as well as suggesting therapeutic potential in HER2+ cancers.
For anyone who missed this video.
Clinical Trial Website Update, page-55
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
